SAGE Therapeutics Inc (NASDAQ:SAGE)
| 20.58 Delayed Data As of Sep 29 |  -0.14 / -0.68%Today’s Change | 16.52 Today|||52-Week Range 59.99 | -46.04% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $1.2B |
Company Description
SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel medicines. It targets diseases and disorders of the brain with three key focus areas: depression, neurology, and neuropsychiatry. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010, and is headquartered in Cambridge, MA.
Contact Information
SAGE Therapeutics, Inc. 215 1st Street Cambridge Massachusetts 02142 |
Employees
Shareholders
| Mutual fund holders | 52.46% |
| Individual stakeholders | 4.49% |
| Other institutional | 37.43% |
Top Executives
| Barry E. Greene | President, Chief Executive Officer & Director |
| Kimi E. Iguchi | Chief Financial & Accounting Officer |
| Al Robichaud | Chief Scientific Officer |
| Amy Schacterle | Senior VP-Research & Development Strategy |
| Matt Lasmanis | Chief Technology & Innovation Officer |
